A former project manager for Neuralstem Inc. was accused by federal securities regulators of tipping off her partner to the negative results of a clinical trial for an antidepressant the company was developing, allowing him and his uncle to dump their shares before the news was announced.
Holly Hand, 35, was a senior project manager for clinical trials at Neuralstem in July 2017 when she allegedly tipped off Chad Calice to the negative results of a trial for NSI-189, an antidepressant that was one of the company’s main drugs under development, according to a lawsuit filed by the
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.